Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells

International Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 146-152

  Brüsselbach, Sabine ^a   Nettelbeck, Dirk M ^a   Sedlacek, Hans Harald ^b   Müller, Rolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; FLAVOPIRIDOL; PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL DEATH; ENDOTHELIUM CELL; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; PIPERIDINES;

EID: 0040379168     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B     Document Type: Article

References (23)

1. ARCARI, P., MARTINELLI, R. and SALVATORE, F., The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucl. Acids Res., 12, 9179-9189 (1984).
2. BIBLE, K.C. and KAUFMANN, S.H., Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56, 4856-4861 (1996).
3. CZECH, J., HOFFMANN, D., NAIK, R. and SEDLACEK, H.H., Antitumoral activity of flavone L 86-8275. Int. J. Oncol., 6, 31-36 (1995).
4. DE AZEVEDO, W.F.J., MUELLER-DIECKMANN, H.J., SCHULZE-GAHMEN, U., WORLAND, P.J., SAUSVILLE, E. and KIM, S.H., Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. nat. Acad. Sci. (Wash.), 93, 2735-2740 (1996).
5. DREES, M., DENGLER, W.A., ROTH, T., LABONTE, H., MAYO, J., MALSPEIS, L., GREVER, M., SAUSVILLE, E.A. and FIEBIG, H.H., Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3, 273-279 (1997).
6. JAFFE, E., Culture and identification of large vessel endothelial cells. In: E. Jaffe (ed.), Biology of endothelial cells, pp 1-13, M. Nijhoff, Boston (1986).
7. KAUR, G., STETLER-STEVENSON, M., SEBERS, S., WORLAND, P., SEDLACEK, H.H., MYERS, C., CZECH, J., NAIK, R. and SAUSVILLE, E.A., Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. nat. Cancer Inst., 84, 1736-1740 (1992).
8. LEE, M.G. and NURSE, P., Complementation used to clone a human homologue of the fisson yeast cell cycle control gene cdc2. Nature (Loud.), 327, 31-35 (1987).
9. LUCIBELLO, F.C., SEWING, A., BRÜSSELBACH, S., BÜRGER, C. and MÜLLER, R., Deregulation of cyclins D1 and E and suppression of cdk2 in senescent human fibroblasts. J. Cell Sci., 105, 123-133 (1993).
10. MATSUSHIME, H., QUELLE, D.E., SHURTLEFF, S.A., SHIBUYA, M., SHERR, C.J. and KATO, J.-Y., D-Type cyclin-dependent kinase activity in mammalian cells. Mol. Cell Biol, 14, 2066-2076 (1994).
11. MÜLLER, R., Transcriptional regulation during the mammalian cell cycle. Trends Genet., 11, 173-178 (1995).
12. PARKER, B.W., SENDEROWICZ, A.M., NIEVES-NEIRA, W., POMMIER, Y. and SAUSVILLE, E.A., DNA fragmentation and apoptosis of lymphoma and prostate carcinoma cell lines after flavopiridol treatment. Proc. Amer. Assoc. Cancer 37, 398 (1996).
13. cdc2. Cell, 58, 833-846 (1989).
14. RABINOVITCH, P.S., KUBBIES, M., CHEN, Y.C., SCHINDLER, D. and HOEHN, H., BrdU-Hoechst flow cytometry: a unique tool for quantitative cell cycle analysis. Exp. Cell Res., 174, 309-318 (1988).
15. 2. Proc. nat. Acad. Sci. (Wash.), 87, 5139-5143 (1990).
16. SCHWARTZ, G.K., FARSI, K., MASLAK, P., KELSEN. D.P. and SPRIGGS, D., Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells, clin. Cancer Res., 3, 1467 (1997).
17. SEDLACEK, H.H., CZECH, J., NAIK, R., KAUR, G., WORLAND, P., LOSIEWICZ, M., PARKER, B., CARLSON, B., SMITH, A., SENDEROWICZ, A. and SAUSVILLE, E.A., Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9, 1143-1168 (1996).
18. SENDEROWICZ, A.M., HEADLEE, D., STINSON, S., LUSH, R.M., TOMPKINS, A. and BRAWLEY, O., Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. Ann. Oncol., 7 (Suppl. 1), 77 (1996).
19. SEWING, A., BÜRGER, C., BRÜSSELBACH, S., SCHALK, C., LUCIBELLO, F.C. and MÜLLER, R., Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP. J. Cell Sci., 104, 545-555 (1993).
20. THORNTON, S.C., MUELLER, S.N. and LEVINE, E.M., Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science, 222, 623-625 (1983).
21. WANG, J., CHENIVESSE, X., HENGLEIN, B. and BRÉCHOT, C., Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature (Loud.), 343, 555-557 (1990).
22. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased HI kinase activity. Biochem. Pharmacol., 46, 1831-1840 (1993).
23. ZWICKER, J. and MÜLLER, R., Cell cycle regulation of gene expression by transcriptional repression. Trends Genet., 13, 3-6 (1997).